Posttreatment FDG PET/CT in predicting survival of patients with ovarian carcinoma.

about

Posttreatment FDG PET/CT in predicting survival of patients with ovarian carcinoma.

Item

http://www.wikidata.org/entity/Q36923202

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Posttreatment FDG PET/CT in predicting survival of patients with ovarian carcinoma.

@en

type

Item

label

Posttreatment FDG PET/CT in predicting survival of patients with ovarian carcinoma.

@en

prefLabel

Posttreatment FDG PET/CT in predicting survival of patients with ovarian carcinoma.

@en

P1476

Posttreatment FDG PET/CT in predicting survival of patients with ovarian carcinoma

@en

P2093

Hao Wang

http://www.w3.org/2001/XMLSchema#string

Hua-Ling Tsai

http://www.w3.org/2001/XMLSchema#string

John Crandall

http://www.w3.org/2001/XMLSchema#string

Mehrbod S Javadi

http://www.w3.org/2001/XMLSchema#string

Richard L Wahl

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2012

Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012

Time-dependent ROC curves for censored survival data and a diagnostic marker.

The impact of PET-CT in suspected recurrent ovarian cancer: A prospective multi-centre study as part of the Australian PET Data Collection Project.

A phase 3 trial of bevacizumab in ovarian cancer.

Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations.

Preoperative [F]FDG PET/CT predicts recurrence in patients with epithelial ovarian cancer.

Diagnostic and prognostic evaluation of fluorodeoxyglucose positron emission tomography/computed tomography and its correlation with serum cancer antigen-125 (CA125) in a large cohort of ovarian cancer patients

FDG-PET for management of cervical and ovarian cancer.

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.

P2888

s13550-016-0194-7

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13550-016-0194-7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Linda C Chu

P577

2016-05-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1038250405

http://www.w3.org/2001/XMLSchema#string

P698

27206785

http://www.w3.org/2001/XMLSchema#string

P932

4875573

http://www.w3.org/2001/XMLSchema#string